ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02326961
Previous Study | Return to List | Next Study

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee (ACT-OA Knee)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02326961
Recruitment Status : Completed
First Posted : December 30, 2014
Last Update Posted : October 28, 2016
Sponsor:
Information provided by (Responsible Party):
Cytori Therapeutics

Brief Summary:
The primary objective of this study is to evaluate the safety and feasibility of intraarticular injection of Celution prepared adipose-derived regenerative cells injected into knees of patients with chronic knee pain due to osteoarthritis.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Device: Celution Device Other: Placebo Phase 2

Detailed Description:

The ACT - OA Knee Clinical Trial is a prospective, randomized, multi-center device trial intended to assess safety and feasibility of intraarticular administration of Celution processed Adipose Derived Regenerative Cells (ADRCs). The study will include 90 patients in up to 15 sites in the United States.

Subjects that have chronic knee pain due to idiopathic osteoarthritis of the knee (confirmed clinically and radiologically) will be evaluated for eligibility in this study. Following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo fat harvest through small volume liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate intraarticular administration. A dose escalation approach has been designed wherein the study is divided into two double-blind, randomized, placebo-controlled parts as follows:

Part A:

Low Dose (20,000,000 cells): 30 patients OR Placebo: 15 patients

Part B:

High Dose (40,000,000 cells): 30 patients OR Placebo: 15 patients

Subjects randomized to placebo will undergo fat harvest and intraarticular injection of a placebo that has been visually matched to the active test substance. All subjects will undergo imaging studies, clinical evaluations, and laboratory testing prior to and after the procedure; patients will be followed for 48 weeks after intraarticular injections are performed.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study
Study Start Date : January 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Celution ADRCs; Low Dose
Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
Device: Celution Device
ADRCs Prepared using the Celution Device

Experimental: Celution ADRCs; High Dose
Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
Device: Celution Device
ADRCs Prepared using the Celution Device

Placebo Comparator: Placebo
Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
Other: Placebo
Inactive Placebo




Primary Outcome Measures :
  1. Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain on Walking [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Observed Pain Scores on 50-foot Walk Test [ Time Frame: 48 Weeks ]
  2. Number of Observed OARS130 Responders [ Time Frame: 48 Weeks ]
  3. Knee Injury and Osteoarthritis Outcome Score (KOOS) [ Time Frame: 48 Weeks ]
  4. VAS Assessments [ Time Frame: 48 Weeks ]
  5. Patient Global Assessment [ Time Frame: 48 Weeks ]
  6. Use of Rescue Medication [ Time Frame: 48 Weeks ]
  7. SF-36 Questionnaire [ Time Frame: 48 Weeks ]
  8. MRI Osteoarthritis Knee Score [ Time Frame: 48 Weeks ]

Other Outcome Measures:
  1. Adverse Events, Serious Adverse Events, and UADEs [ Time Frame: 48 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females ≥ 40 and < 70 years of age
  2. Able to provide written informed consent
  3. Diagnosis of osteoarthritis in one or both knees by American College of Rheumatology (ACR) criteria
  4. Kellgren and Lawrence grade 2 or 3 (standing AP x-ray) of the target knee within the preceding 6 months
  5. Pain due to osteoarthritis in the target knee ≥ 6 months
  6. Minimum score of "moderate" from KOOS question about pain on walking on a flat surface.
  7. Minimum score of "moderate" from KOOS question about degree of difficulty during walking on a flat surface.
  8. Continued knee pain and limitations in knee function despite prescription of conservative therapy for at least 6 months.
  9. Ability to safely undergo liposuction that will result in the harvest of a sufficient quantity of adipose tissue (approximately 300 mL)
  10. On stable regimen of one analgesic medication (rescue medication) for their knee pain due to osteoarthritis and ability and willingness to use the same analgesic medication during the study (screening period through to final study visit).
  11. Ability to perform procedures required of the pain index evaluations (unassisted walking 50 feet on a flat surface and going up and down stairs)

Exclusion Criteria:

  1. Any major injury to the target knee within the 12 months prior to the screening visit
  2. Need for cane or other assistance device for walking
  3. Any surgery to the target knee within the 6 months prior to the screening visit, or surgery to the contralateral knee or other weight-bearing joint if it will interfere with knee assessments
  4. Prior articular transplant procedures
  5. Prior ligament reconstruction to the target knee within 12 months prior to the screening visit
  6. Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or psoriatic arthritis
  7. Gout or calcium pyrophosphate (pseudogout) diseases that have flared within the previous 6 months prior to the screening visit
  8. X-ray findings of acute fractures, known severe loss of bone density (as determined by the investigator), avascular necrosis, and/or severe bone or joint deformity in the target knee (>5 degree valgus or varus deviation from mechanical axis)
  9. Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or vascular claudication
  10. Primary knee pain due to diagnosed isolated patella-femoral arthritis or chondromalacia in the target knee
  11. Significant target knee joint infection or skin disorder/infection within the previous 6 months prior to the screening visit
  12. Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation of the target knee
  13. Any condition requiring immunosuppressive medication or use of systemic steroids
  14. Intra-articular injection of steroids in previous 3 months or hyaluronic acid in previous 6 months in one or both knees prior to the screening visit
  15. Patients that have received PRP, other platelet-based product, or investigational treatment in another cell/biologic study for the targeted treatment injury in the 12 months prior to the injection procedure
  16. Participation in any experimental drug or device study within the 6 months prior to the screening visit
  17. Obesity defined as BMI > 35 kg/m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02326961


Locations
United States, Arizona
Arizona Arthritis and Rheumatology Research, PLLC
Mesa, Arizona, United States, 85202
United States, Arkansas
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States, 72205
United States, California
BioSolutions Clinical Research Center
La Mesa, California, United States, 91942
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Kansas
Heartland Research Associates
Wichita, Kansas, United States, 67207
United States, Kentucky
Central Kentucky Research Associates
Lexington, Kentucky, United States, 40509
United States, Louisiana
Covington Orthopedic and Sports Medicine Institute
Covington, Louisiana, United States, 70433
United States, Maryland
Arthritis Treatment Center
Frederick, Maryland, United States, 21702
United States, Missouri
Center for Pharmaceutical Research
Kansas City, Missouri, United States, 64114
United States, New York
Hospital for Special Surgery
New York, New York, United States, 10021
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Sponsors and Collaborators
Cytori Therapeutics
Investigators
Study Director: Steven Kesten, MD Cytori Therapeutics

Responsible Party: Cytori Therapeutics
ClinicalTrials.gov Identifier: NCT02326961     History of Changes
Other Study ID Numbers: ACT-OA Knee
First Posted: December 30, 2014    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016

Keywords provided by Cytori Therapeutics:
osteoarthritis
knee
adipose derived regenerative cells
ADRC
Celution
arthritis

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases